PHI
PLDT Inc.
PHI has lower modeled downside risk, despite its lower overall score.
RDDT
Reddit, Inc.
RDDT has the edge over PHI overall, supported by stronger fundamentals and stronger modeled upside.
PHI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Under pressure |
PHI's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
RDDT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
RDDT's revenue, profitability, cash flow and balance sheet are all currently healthy.
PHI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 7.8x | $16.13 | — |
| Cheap | 8.6x | $17.63 | +9.3% |
| Fair | 11x | $22.25 | +38% |
| Expensive | 22x | $46.34 | +187% |
Historical ranges are pointers, not guarantees.
PHI has the edge over RDDT in the historical PE scenario, which offers more potential upside but is not a forecast.
RDDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $99.55 | — |
| Current | 20x | $99.55 | — |
| Cheap | 35x | $171 | +72% |
| Fair | 46x | $228 | +129% |
| Expensive | 53x | $262 | +163% |
Historical ranges are pointers, not guarantees.
RDDT's PE is 20x, but its earnings don't support one, so it isn't a reliable read right now.
PHI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect PHI's earnings and profitability to decline, with its revenue holding steady.
RDDT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Low |
RDDT has the edge over PHI on the outlook, with more favorable earnings and revenue expectations.
PHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $2.06 | -12% |
| Q1 2026 | $2.17 | -5.2% |
| Q4 2025 | $2.18 | -7.2% |
| Q3 2025 | $2.13 | +9.2% |
| Q2 2025 | $2.33 | +21% |
| Q1 2025 | $2.29 | +15% |
| Q4 2024 | $2.35 | +21% |
| Q3 2024 | $1.95 | +144% |
PHI has the stronger earnings trend. Trailing diluted EPS is down 12% for PHI versus RDDT down 39%.
RDDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.32 | +29% |
| Q3 2024 | -$7.98 | -$7.17 |
| Q2 2024 | -$8.19 | -$7.15 |
| Q1 2024 | -$8.38 | -$7.25 |
| Q4 2023 | -$0.56 | +$0.41 |
| Q3 2023 | -$0.81 | -$0.02 |
| Q2 2023 | -$1.04 | -$0.48 |
| Q1 2023 | -$1.13 | -$0.48 |
| Q4 2022 | -$0.97 | -$0.19 |
RDDT has returned to profit: it earned $4.90 per share over the past year, after losing money the year before.
PHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $873.8M | +2.2% |
| Q1 2026 | $889.9M | +2.2% |
| Q4 2025 | $864.8M | -1.7% |
| Q3 2025 | $845.7M | +0.7% |
| Q2 2025 | $855M | +1.8% |
| Q1 2025 | $870.4M | +1.9% |
| Q4 2024 | $880.1M | +2.4% |
| Q3 2024 | $840.2M | +2% |
PHI's revenue grew through 2022 and has held roughly level since: $874M last quarter, up 2.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 52% | +25 points |
| Q1 2026 | 50% | +22 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 52% | +46 points |
| Q2 2025 | 27% | +3.8 points |
| Q1 2025 | 28% | -0.6 points |
| Q4 2024 | 18% | -25 points |
| Q3 2024 | 5.8% | -46 points |
PHI has the edge over RDDT on profitability, with a higher operating margin.
RDDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $895M | +53% |
| Q2 2026 | $804.9M | +61% |
| Q1 2026 | $663.4M | +69% |
| Q4 2025 | $725.6M | +70% |
| Q3 2025 | $584.9M | +68% |
| Q2 2025 | $499.6M | +78% |
| Q1 2025 | $392.4M | +61% |
| Q4 2024 | $427.7M | +71% |
RDDT has the edge over PHI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 29% | +5.5 points |
| Q2 2026 | 29% | +15 points |
| Q1 2026 | 28% | +27 points |
| Q4 2025 | 32% | +20 points |
| Q3 2025 | 24% | +22 points |
| Q2 2025 | 14% | +25 points |
| Q1 2025 | 1% | +244 points |
| Q4 2024 | 12% | +11 points |
RDDT's operating margin was 29% last quarter, up 5.5 points from the same quarter a year ago, near the top of its range since 2020.
PHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $183.9M | +176% |
| Q1 2026 | $115.6M | -13% |
| Q4 2025 | $134.2M | +$228.6M |
| Q3 2025 | $173.9M | +88% |
| Q2 2025 | $66.5M | -51% |
| Q1 2025 | $132.3M | +68% |
| Q4 2024 | -$94.4M | -172% |
| Q3 2024 | $92.4M | -54% |
PHI generated $608M in free cash flow over the past year, about three times what it generated the year before.
RDDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $362.6M | +98% |
| Q2 2026 | $260.7M | +135% |
| Q1 2026 | $311.2M | +146% |
| Q4 2025 | $263.6M | +196% |
| Q3 2025 | $183.1M | +161% |
| Q2 2025 | $110.8M | +308% |
| Q1 2025 | $126.6M | +333% |
| Q4 2024 | $89.2M | +$111.2M |
RDDT has the edge over PHI on cash flow, with more consistent year-over-year improvement.
PHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -428K shares |
| 1 year | -0.2% | -442K shares |
| 3 years | 0% | -5K shares |
| 5 years | -0.2% | -520K shares |
| Available history | -0.5% | -1M shares |
PHI has 216M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
PHI hasn't bought back shares in the past year.
RDDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -169K shares |
| 1 year | -0.4% | -868K shares |
| 3 years | +24% | +38.5M shares |
| 5 years | +24% | +38.5M shares |
RDDT has the edge over PHI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100.4M |
| Q2 2026 | $234.6M |
| Q1 2026 | $5M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $4.2M |
| Q4 2022 | — |
PHI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 3.2x | Elevated |
| Q1 2026 | 3.2x | Elevated |
| Q4 2025 | 3.7x | Elevated |
| Q3 2025 | 3.1x | Elevated |
| Q2 2025 | 3.0x | Moderate |
| Q1 2025 | 3.0x | Moderate |
| Q4 2024 | 3.1x | Elevated |
| Q3 2024 | 3.4x | Elevated |
PHI's net debt is about 3.2 years of its operating earnings (EBITDA), up from 3.0 years a year ago.
RDDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
| Q2 2026 | -1.9x | Net Cash |
| Q1 2026 | -2.2x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -3.3x | Net Cash |
| Q2 2025 | -5.0x | Net Cash |
| Q1 2025 | -13.1x | Net Cash |
RDDT has the edge over PHI on leverage, with a lower net debt burden relative to earnings.
PHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 24.6 | Neutral |
PHI's weekly RSI is 36 (neutral) and its Stochastic is 25 (neutral).
RDDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 6.5 | Oversold |
RDDT's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
PHI PE vs Communication Services Sector
| Metric | PHI | Sector median | Relative |
|---|---|---|---|
| PE | 7.8x | 16x | 53% below |
| PE % | 5 | 26 | 21 pts below |
PHI has the edge over RDDT on valuation relative to its sector.
RDDT PE vs Communication Services Sector
| Metric | RDDT | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 16x | 23% above |
| PE % | 5 | 23 | 18 pts below |
RDDT is trading at 20x earnings, a 23% premium to the Communication Services sector's median of 16x, though its earnings don't support one.
PHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.0 | 10% below |
| 20 week MA | $18.6 | 13% below |
| 50 week MA | $20.0 | 20% below |
| 100 week MA | $21.0 | 23% below |
| 200 week MA | $22.4 | 28% below |
RDDT has stronger trend alignment. PHI is above 0 of 5 weekly averages versus RDDT above 0 of 4.
RDDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $130.6 | 24% below |
| 20 week MA | $151.7 | 34% below |
| 50 week MA | $165.0 | 40% below |
| 100 week MA | $167.1 | 40% below |
RDDT is in a downtrend: it's below all four of its weekly moving averages, and 40% below its 100-week average.
PHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.8 | $28.0 | +41% |
| 2021 | $28.0 | $37.0 | +32% |
| 2022 | $37.0 | $22.7 | -39% |
| 2023 | $22.7 | $23.4 | +3.4% |
| 2024 | $23.4 | $22.1 | -5.8% |
| 2025 | $22.1 | $21.7 | -1.9% |
| 2026 YTD | $21.7 | $16.1 | -26% |
PHI has the edge over RDDT on returns for 2026, with the stronger performance.
RDDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $46.0 | $173.5 | +277% |
| 2025 | $173.5 | $225.8 | +30% |
| 2026 YTD | $225.8 | $99.6 | -56% |
RDDT has finished every year since 2024 higher, and it's down 56% so far in 2026.